BID | 79.36 | ASK | 79.42 | ||
Open | 80.37 | Previous Close | 80.04 | ||
Pre-Market | 80.16 | After-Market | - | ||
0.12 0.15% | - - |
Target Price | 94.64 | Analyst Rating | Moderate Buy 1.60 | |
Potential % | 18.49 | Finscreener Ranking | ★★★★ 53.30 | |
Insiders Trans % 3/6/12 mo. | -/-100/-91 | Value Ranking | ★★★★ 56.66 | |
Insiders Value % 3/6/12 mo. | -/-100/-92 | Growth Ranking | ★★★★ 60.33 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-91 | Income Ranking | ★★+ 44.95 | |
Market Cap | 40.55B | Earnings Rating | Sell | |
Price Range Ratio 52W % | 39.40 | Earnings Date | 4th Feb 2021 |
Today's Price Range 79.3680.65 | 52W Range 69.1095.19 | 5 Year PE Ratio Range 4.9072.60 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | -0.65% | ||
1 Month | -1.01% | ||
3 Months | -1.10% | ||
6 Months | -8.03% | ||
1 Year | -11.28% | ||
3 Years | 14.33% | ||
5 Years | 127.01% | ||
10 Years | 232.01% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 22.37 | |||
ROE last 12 Months | 10.89 | |||
ROA (5Y Avg) | 10.11 | |||
ROA last 12 Months | 4.71 | |||
ROC (5Y Avg) | 15.02 | |||
ROC last 12 Months | 6.94 | |||
Return on invested Capital Q | 2.55 | |||
Return on invested Capital Y | 8.49 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 4.30 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
45.20 | ||||
4.77 | ||||
4.81 | ||||
20.80 | ||||
-314.50 | ||||
3.84 | ||||
10.77 | ||||
16.77 | ||||
43.50B | ||||
Forward PE | 23.27 | |||
PEG | 4.91 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.90 | ||||
2.60 | ||||
0.42 | ||||
0.81 | ||||
7.00 | ||||
Leverage Ratio | 2.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
38.00 | ||||
8.70 | ||||
15.80 | ||||
18.50 | ||||
11.06 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
8.49B | ||||
16.62 | ||||
-4.16 | ||||
-4.26 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.22 | ||||
0.98 | ||||
14.64 | ||||
-3.43 | ||||
Payout ratio | 50.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2020 | 0.73 | 0.83 | 13.70 |
Q02 2020 | 0.71 | 0.64 | -9.86 |
Q01 2020 | 0.73 | 0.82 | 12.33 |
Q04 2019 | 0.88 | 0.97 | 10.23 |
Q02 2019 | 0.81 | 0.89 | 9.88 |
Q01 2019 | 0.68 | 0.76 | 11.76 |
Q04 2018 | 0.73 | 0.78 | 6.85 |
Q03 2018 | 0.74 | 0.80 | 8.11 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2020 QR | 0.75 | -13.79 | Negative |
12/2020 FY | 3.04 | -0.33 | Negative |
3/2021 QR | 0.74 | -10.84 | Negative |
12/2021 FY | 3.44 | -4.71 | Negative |
Next Report Date | 4th Feb 2021 |
Estimated EPS Next Report | 0.75 |
Estimates Count | 10 |
EPS Growth Next 5 Years % | 9.20 |
Volume Overview | |
---|---|
Volume | 101.35K |
Shares Outstanding | 510.82M |
Trades Count | 404 |
Dollar Volume | 10.79M |
Avg. Volume | 2.45M |
Avg. Weekly Volume | 2.41M |
Avg. Monthly Volume | 2.24M |
Avg. Quarterly Volume | 3.09M |
Baxter International Inc. (NYSE: BAX) stock closed at 80.04 per share at the end of the most recent trading day (a -0.01% change compared to the prior day closing price) with a volume of 1.65M shares and market capitalization of 40.55B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 50000 people. Baxter International Inc. CEO is Jose E. Almeida.
The one-year performance of Baxter International Inc. stock is -11.28%, while year-to-date (YTD) performance is -0.25%. BAX stock has a five-year performance of 127.01%. Its 52-week range is between 69.1 and 95.19, which gives BAX stock a 52-week price range ratio of 39.40%
Baxter International Inc. currently has a PE ratio of 45.20, a price-to-book (PB) ratio of 4.77, a price-to-sale (PS) ratio of 4.81, a price to cashflow ratio of 20.80, a PEG ratio of 2.32, a ROA of 4.71%, a ROC of 6.94% and a ROE of 10.89%. The company’s profit margin is 11.06%, its EBITDA margin is 15.80%, and its revenue ttm is $8.49 Billion , which makes it $16.62 revenue per share.
Of the last four earnings reports from Baxter International Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.75 for the next earnings report. Baxter International Inc.’s next earnings report date is 04th Feb 2021.
The consensus rating of Wall Street analysts for Baxter International Inc. is Moderate Buy (1.6), with a target price of $94.64, which is +18.49% compared to the current price. The earnings rating for Baxter International Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Baxter International Inc. has a dividend yield of 1.22% with a dividend per share of $0.98 and a payout ratio of 50.00%.
Baxter International Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.87, ATR14 : 6.43, CCI20 : -38.42, Chaikin Money Flow : 538.18, MACD : 0.50, Money Flow Index : 61.17, ROC : 1.06, RSI : 52.54, STOCH (14,3) : 31.65, STOCH RSI : 0.00, UO : 54.56, Williams %R : -68.35), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Baxter International Inc. in the last 12-months were: Albert P L Stroucken (Option Excercise at a value of $104 846), Albert P L Stroucken (Sold 4 320 shares of value $344 027 ), Andrew Frye (Sold 3 742 shares of value $340 522 ), Cristiano Franzi (Option Excercise at a value of $2 899 918), Cristiano Franzi (Sold 46 600 shares of value $4 083 879 ), Giuseppe Accogli (Option Excercise at a value of $3 552 302), Giuseppe Accogli (Sold 72 341 shares of value $6 148 985 ), James R. Gavin (Option Excercise at a value of $1 136 578), James R. Gavin (Sold 29 798 shares of value $2 574 732 ), Jeanne K. Mason (Option Excercise at a value of $1 365 819), Jeanne K. Mason (Sold 47 146 shares of value $4 390 608 ), John D. Forsyth (Option Excercise at a value of $197 251), John D. Forsyth (Sold 6 310 shares of value $504 863 ), Peter S. Hellman (Sold 0 shares of value $-209 693 ), Peter S. Hellman (Sold 8 640 shares of value $688 284 ), Sean B.W. Martin (Buy at a value of $803 818)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Baxter manufactures medical products across seven major reported business segments. The renal segment (33% of 2018 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (24% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segments (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (7% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining 5% of sales.
CEO: Jose E. Almeida
Teplephone: +1 224 948-2000
Address: One Baxter Parkway, Deerfield 60015, IL, USA
Number of employees: 50 000
Copyright (c) 2021. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE BZX (BATS) real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2021. All market data is provided by Barchart Solutions. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.